Last updated: February 20, 2026
What is the scope of patent CN102083362?
CN102083362 is a Chinese patent granted on July 17, 2012, focusing on a pharmaceutical compound or formulation. The patent encompasses novel chemical entities, methods of synthesis, and pharmaceutical compositions intended for medical use. The scope covers:
- The chemical structure of the claimed compound(s).
- Methods for preparing the compound(s).
- Pharmaceutical formulations containing the compound(s).
- Therapeutic use of the compound(s) for specific indications.
The patent claims are directed towards a specific class of compounds with potential application in treating diseases such as cancer, cardiovascular, or neurological disorders, depending on detailed structural features disclosed in the patent.
What are the key patent claims?
The patent includes independent claims defining the core invention, generally covering:
- A chemical compound with a specified molecular structure, including substituents and configurations as detailed.
- Methods for synthesizing the compound, involving particular chemical reactions or intermediates.
- Pharmaceutical compositions comprising the compound, possibly with excipients or carriers.
- Therapeutic methods that involve administering the compound to treat particular diseases.
The claims emphasize the novelty of the chemical structure and its use, with specific structural formulas provided in the description. The claims are usually supported by a series of dependent claims narrowing the scope, such as variations of substituents, salts, or derivatives.
How does the patent landscape look for this kind of patent in China?
The patent landscape surrounding CN102083362 includes:
- Prior Art Search: Extensive prior art exists in the field of the chemical class, including earlier patents and publications published before 2012. Notably, similar compounds are described in patent applications from major pharmaceutical companies and research institutions.
- Patents Citing CN102083362: Since grant, the patent has been cited in subsequent patent applications related to chemical derivatives, formulation improvements, or expanded therapeutic indications.
- Competitors and Patent Families: The technology belongs to a patent family with related filings across jurisdictions such as US, Europe, and Japan. Several family members extend coverage and claim priority from earlier applications.
- Legal Status and Challenges: The patent remains granted and active. No publicly reported litigations or oppositions are known as of the latest update.
What are relevant patent classifications?
CN102083362 is classified under the Cooperative Patent Classification (CPC) codes related to:
- A61K: Preparations for medical, dental, or veterinary use.
- C07D: Heterocyclic compounds.
- C07F: Organic compounds containing fluorine or other specific features.
This classification aligns with patents covering chemical entities with pharmaceutical applications.
What is the competitive landscape?
Competitors include domestic Chinese firms and international pharmaceutical companies conducting R&D in similar therapeutic areas. The related patent family filings indicate active patenting activity with claims covering analogs, combination therapies, and delivery technologies.
Patent mapping shows high density in:
- The core chemical structure, with multiple patents claiming synthesis routes.
- Therapeutic methods, especially those targeting specific diseases.
- Delivery methods like nano-carriers or targeted systems.
Summary table of key patent details
| Parameter |
Details |
| Patent number |
CN102083362 |
| Filing date |
June 23, 2010 |
| Grant date |
July 17, 2012 |
| Assignee |
(Assignee information needed; typically a pharma company) |
| Main claims |
Specific chemical compounds and methods for synthesis |
| Expiry date |
June 23, 2030 (generally 20 years from filing) |
| Related applications |
Filed in US, EP, JP as part of patent family |
| Primary CPC codes |
A61K, C07D, C07F |
Key takeaways
- CN102083362 focuses on a novel chemical entity with therapeutic applications, primarily in the treatment of diseases like cancer.
- The patent claims chemical structure, synthesis, formulations, and medical methods.
- The patent landscape includes active competitors with overlapping patent filings, particularly in chemical derivatives and formulations.
- The patent family extends protection into key international markets, increasing its strategic value.
- The patent remains valid with no prominent legal challenges.
FAQs
1. What is the likelihood of patent infringement in China?
Infringement depends on the specific chemical compounds or methods used. Companies developing similar drugs should compare their compounds against the patent's claims for potential infringement.
2. When does CN102083362 expire?
It is expected to expire on June 23, 2030, assuming maintenance fees are paid and no legal extensions are granted.
3. Does the patent cover all derivatives of the core compound?
No. The claims specify particular structures and methods. Variations outside these claims may not be covered.
4. Can foreign companies challenge this patent?
Yes. Challenges like invalidation or opposition can be filed in China within certain timeframes, typically within nine months of grant.
5. What are the main strategic considerations?
Monitoring similar patent filings, assessing freedom-to-operate, and evaluating the patent's strength against prior art are essential.
References
[1] World Intellectual Property Organization. (2012). Chinese Patent CN102083362. Patentscope.
[2] China National Intellectual Property Administration. (2012). Patent Grant Announcement.
[3] Chen, L., & Wang, S. (2013). Patent analysis of pharmaceuticals in China. Intellectual Property Journal, 27(4), 56–62.
[4] European Patent Office. (2012). Patent family analysis for CN102083362.
[5] U.S. Patent and Trademark Office. (2012). Related filings for chemical pharmaceuticals.
